LOGIN  |  REGISTER
Chimerix

Waters Launches Most Sensitive and Compact Clinical IVD System with Xevo TQ Absolute IVD Mass Spectrometer

April 04, 2023 | Last Trade: US$357.77 13.06 3.79

News Summary:

  • Waters adds the Xevo TQ Absolute IVD System to its MassTrak IVD portfolio of LC-MS/MS systems, making it the most sensitive benchtop tandem quadrupole (TQ) mass spectrometer for clinical applications.i
  • Provides up to five times the sensitivity of instruments in its class,ii with lower detection limits for analyzing trace-level analytes in smaller sample volumes.
  • Its sustainable design is 45% smaller and uses 50% less nitrogen gas and electricity than comparable TQ-MS systems.iii

MONTEREY, Calif. / Apr 04, 2023 / Business Wire / MSACL Conference 2023-- Waters Corporation (NYSE:WAT) today unveiled its next generation Xevo TQ Absolute IVD mass spectrometer, expanding its family of MassTrak IVD LC-MS/MS Systems for clinical diagnostic applications.

The powerful analytical performance of the Xevo TQ Absolute IVD mass spectrometer is up to five times more sensitive for quantifying clinical analytes than similar commercial instruments on the market. This sensitivity enables clinical laboratories to detect and measure trace level analytes within a sample at the lowest detection levels than previously possible.iv It can extend the testing capabilities of the clinical laboratory to include lower volume samples obtained in less-invasive assays such as saliva, breath, and dried blood spots. The system also enables clinical laboratories to expand their test menu to include multiplex panels and large molecules.

“Waters’ MassTrak IVD systems gives clinical diagnostic laboratories highly precise and flexible options that ultimately enable clinicians to provide better patient care,” said Jianqing Bennett, Waters Corporation Senior Vice President of the Waters Clinical Business Unit. “Adding the Xevo TQ Absolute IVD to the MassTrak IVD family offers customers class-leading sensitivity and analytical performance. Waters is uniquely positioned to enable clinical laboratories to develop reliable test methods for difficult analytes, helping them expand their capabilities to manage emerging remote sampling techniques.”

The new MassTrak LC-MS/MS IVD system includes the ACQUITY UPLC I-Class PLUS liquid chromatography instrument with the Xevo TQ Absolute IVD mass spectrometer. The ACQUITY UPLC I-Class PLUS System is designed to deliver rapid and accurate sample analysis to enhance the sensitivity of any mass spectrometer and simplify the characterization of the most complex sample. The Xevo TQ Absolute IVD System provides more consistent instrument-to-instrument performance, with a user-friendly design that maximizes service uptime. Its innovative design is also 45% smaller and uses 50% less nitrogen gas and electricity than comparable tandem quadrupole-mass spectrometry (TQ-MS) systems,v making it ideal for hospital labs and independent commercial labs with both sustainability and business growth goals to meet.

Additional Resources

About Waters Corporation (www.waters.com)

Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for over 60 years. With more than 8,200 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.

___________________
i Waters comparison of TQ Absolute IVD vs. existing Waters TQ-XS IVD and the SCIEX 6500 IVD, which are the next two most sensitive IVD-compliant tandem quadrupole products currently available for commercial sale.
ii See endnote i above
iii Based on a comparison of product specifications for the Sciex 7500, Sciex 6500, Agilent 6495C, and Thermo TSQ Altis.
iv See endnote i above
v See endnote iii above

photo

C4 Therapeutics

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB